CATTEL, Luigi

CATTEL, Luigi  

Dip. SCIENZA E TECNOLOGIA DEL FARMACO (attivo dal 01/01/1900 al 30/04/2013)  

Mostra records
Risultati 1 - 20 di 248 (tempo di esecuzione: 0.046 secondi).
Titolo Data di pubblicazione Autore(i) File
(E) and (Z)-29-methylidene-2,3-oxidosqualene as stereospecific mechanism-based inhibitors of 2,3-oxidosqualene cyclase. 1997 Ceruti M.; Rocco F.; Cattel L.
10 and 19-azasqualene derivatives as irreversible inhibitors of 2,3-oxidosqualene cyclase from pig liver. 1995 Ceruti M.; Viola F.; Balliano G.; Rocco F.; Cattel L.
2,3,4,5-tetrahydroxy-5-(4-hydroxyphenyl)valeric acid: a new cleavable monofunctional reagent for monoclonal antibody labeling. 1994 Grosa G.; Ceruti M.; Dosio F.; Brusa P.; Cattel L.
2,3-oxidosqualene cyclase and squalene epoxidase, as target enzymes for the development of new sterol biosynthesis inhibitors 1991 Cattel L.; Ceruti M.; Balliano G.; Viola F.
2,3-oxidosqualene cyclase and squalene epoxidase, as target enzymes for the development of new sterol biosynthesis inhibitors. 1991 Cattel L.; Ceruti M.; Balliano G.; Viola F.
2,3-oxidosqualene cyclase from yeast: a target enzyme for drug discovery. 1996 Milla P.; Balliano G.; Ceruti M.; Cattel L.
2-Aza-2,3-dihydrosqualene and its N-oxide as inhibitors of sterol biosynthesis in bramble cell suspension cultures. 1985 Ceruti M.; Cattel L.; Schmitt P.; Benveniste P.
A new 'blocked' immunotoxin 1987 L. Cattel; P.M. Comoglio; L. Delprino; P. Brusa; F. Dosio; M. Prat
A new approach in the synthesis of immunotoxins: ribosome inactivating protein non-covalently bound to monoclonal antibody 1993 F. Dosio; P. Brusa; L. Cattel
A new class of linkers: open chain thioimidate derivatives 1991 L. Cattel; M. Giacomotti; F. Dosio; P. Brusa; L. Delprino
A new generation of immunotoxins: cytotoxins non-covalently bound to monoclonal antibodies 1992 F. Dosio; P. Brusa; L. Cattel
A new method to synthesize immunotoxins using non-covalent interactions 1992 F. Dosio; P. Brusa; L. Cattel
A Pharmacokinetics Study to Optimize Intravesical Administration of Gemcitabine 2008 Paolo Gontero; Luigi Cattel; Tonia C. Paone; Giovanna Berta; Paola Milla; Francesco Carbone; Claudio Medana; Alessandro Tizzani
A pharmacokinetics study to optimize intravesical administration of gemcitabine 2009 Paolo Gontero; Luigi Cattel; Giovanna Berta; Tonia C. Paone; Paola Milla; Claudio Medana; Francesco Carbone; Alessandro Tizzani
A unique squalenoylated and nonpegylated doxorubicin nanomedicine with systemic long-circulating properties and anticancer activity. 2014 S. Mura; A. Maksimenko; F. Dosio; J. Mougin; A. Ferrero; S. Wack; L.H. Reddy; A.A. Weyn; E. Lepeltier; C. Bourgaux; B. Stella; L. Cattel; P. Couvreur
Active targeting of squalenic nanoparticles 2009 S. Bolognesi; B. Stella; F. Dosio; A. Ferrero; L. Cattel
Administration of reduced glutathione in FOLFOX4 regimen in advanced colorectal cancer: effect on oxaliplatin pharmacokinetics and on Pt-DNA adducts formation 2007 M. Airoldi; P. Milla; L. Cattel; I. Gozzelino; A. Drescher; U. Jaehde; L. Branciforte; F. Pedani
Alterata glicosilazione delle IgA sieriche in pazienti affetti da nefropatia a depositi di IgA 1994 P. Cirina; P. Brusa; A. Amore; L. Peruzzi; B. Gianoglio; L. Cattel; R. Coppo
Alterata glicosilazione delle IgA sieriche in pazienti affetti da nefropatia a depositi di IgA 1994 P. Cirina; P. Brusa; A. Amore; L. Peruzzi; B. Gianoglio; L. Cattel; M. Saitta; R. Coppo; GC. Fiorucci
Alterata glicosilazione delle IgA sieriche in pazienti affetti da nefropatia a depositi IgA 1994 P. Cirina; P. Brusa; A. Amore; L. Peruzzi; B. Gianoglio; L. Cattel; R. Coppo